7000 Shoreline Court, Suite 201
South San Francisco
About Tricida, Inc.
Tricida, Inc. is a privately-held, late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). We are led by a management team with an accomplished and proven track record in discovering, developing, and commercializing new therapeutics, with extensive experience in building successful companies around strong science and unmet medical needs. The company is backed by world-class venture capital firms. We are expanding our existing group of exceptionally talented and well-motivated colleagues to develop and commercialize our first-in-class drug candidate, TRC101.
We recently completed enrollment in a pivotal Phase 3 clinical trial (TRCA-301) of TRC101 for the chronic treatment of metabolic acidosis. The TRCA-301 trial was designed to serve as the basis for the submission of a U.S. New Drug Application for TRC101. The application will be submitted under the Accelerated Approval Program, which was created by the U.S. Food and Drug Administration (FDA) to provide a mechanism for earlier approval based on a surrogate endpoint for drugs that treat serious conditions and fill an unmet medical need.
Tricida represents the best of both worlds – offering the exciting intensity and dynamics of a rapidly growing “older” startup, but with the financial resources of a larger organization! We need you to round out our team of exceptionally talented and motivated colleagues striving to make a big impact! Tricida’s shared culture of teamwork, camaraderie and empowerment is evident in the drive and focus our employees demonstrate, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD.
Competitive Compensation and Benefits include: Medical, Dental, and Vision Coverages, Life, AD&D, Disability, 401(k), Flexible Spending Plan, and Pre-IPO stock options. 15 vacation days per year and 11 paid holidays per year, which includes 1 floating holiday. Numerous employee perks.
48 articles with Tricida, Inc.
Tricida to Report Long-Term Clinical Trial Results for TRC101 in CKD Patients with Metabolic Acidosis and Host Conference Call and Webcast on Thursday, March 28, 2019
Tricida, Inc. announced that it will report results from its blinded, 40-week extension trial, TRCA-301E, tomorrow morning at 7:15 am Eastern Time.
Tricida to Report Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 28, 2019
Tricida, Inc. announced that it will report its fourth quarter and the year ended December 31, 2018 financial results at 7:00 am Eastern Time on Thursday, March 28, 2019.
Geoff Parker, Tricida’s Chief Financial Officer, will provide a company overview, business update and progress on the company’s key initiatives.
Dr. Cantrell will lead Tricida’s commercial planning and operations functions.
Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 37th Annual J. P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 11:30 am PT / 2:30 pm ET. Gerrit Klaerner, Ph.D., Tricida’s chief executive officer and president, will provide a company overview, business update and progress on the company’s key initiatives.
Advanced Key Initiatives for NDA Submission
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Thursday, November 8, 2018
Tricida, Inc. announced that it will report its third quarter 2018 financial results after the close of market on Thursday, November 8, 2018.
Tricida Announces Presentation of TRCA-301 Pivotal Trial Results at the American Society of Nephrology Kidney Week Meeting in San Diego, October 23 - 28
Oct. 4, 2018 20:26 UTC Tricida Announces Presentation of TRCA-301 Pivotal Trial Results at the American Society of Nephrology Kidney Week Meeting in San Diego, October 23 - 28 SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer designed to treat metabolic acidosis in patients with
Completed Positive Pivotal Phase 3 Trial for TRC101
Dr. Parsell will lead Tricida’s clinical development of TRC101
Tricida Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Tricida, Inc. (NASDAQ: TCDA), a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-dosed polymer drug designed to treat metabolic acidosis in patients with...
It’s been a pretty good year for biotech initial public offerings (IPOs), with two Bay Area biotechs marking numbers eight and nine for the area.
Tricida, a late-stage biotech company developing therapies for conditions associated with chronic kidney disease (CKD), filed late Monday with the Securities and Exchange Commission to raise up to $150 million in an initial public offering.
Tricida Announces Positive Pivotal Phase 3 Clinical Trial Results for TRC101 in CKD Patients With Metabolic Acidosis
Tricida, Inc., a late-stage pharmaceutical company, announced results from its pivotal Phase 3 double-blind, randomized, placebo-controlled, multi-center Phase 3 clinical trial, TRCA-301, in 217 chronic kidney disease (CKD) patients with metabolic acidosis.
Ms. Falberg is a seasoned pharmaceutical industry executive with extensive leadership and finance expertise.
Tricida, Inc. announced today that it has entered into a $100 million venture debt facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customizing debt financing for companies in the life sciences and technology-related markets.
Tricida Announces Hiring of Jeroen van Beek, Ph.D., as Chief Commercial Officer and Senior Vice President
Dr. van Beek will lead Tricida’s commercial planning and operations functions.
Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101.
Tricida Announces Podium Presentation at ASN Kidney Week 2017 of TRC101 Phase I/II Study Results in Patients With Metabolic Acidosis Associated with Chronic Kidney Disease
Tricida today announced that David A. Bushinsky, M.D., will deliver a podium presentation at the ASN Annual Kidney Week meeting, taking place November 1-5, 2017 in New Orleans, on the results of Tricida’s successful Phase 1/2 study of TRC101.